This Article Full Text (PDF) All Versions of this Article: 1352458507088105v1 14/6/759    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Google Scholar Articles by Sternberg, Z Articles by Munschauer, F PubMed PubMed Citation Articles by Sternberg, Z Articles by Munschauer, F Social Bookmarking                   What's this?

Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity

Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA, zs2{at}buffalo.edu

B Weinstock-Guttman

Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA

D Hojnacki

Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA

P Zamboni

Vascular Disease Center, University of Ferrara, Ferrara, Italy

R Zivadinov

Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA

K Chadha

Department of Molecular & Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

A Lieberman

Department of Molecular & Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

L Kazim

Biopolymer Facility & Mass Spectrometry, Roswell Park Cancer Institute, Buffalo, NY, USA

A Drake

Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA

P Rocco

Department of Social & Preventive Medicine, University of Buffalo, Buffalo, NY, USA

E Grazioli

Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA

F Munschauer

Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA

Objectives

To compare serum levels of the receptor for advanced glycation end products (sRAGE) between multiple sclerosis (MS) patients and healthy control subjects, and to investigate whether serum sRAGE levels correlate with MS disease severity as indicated by the Kurtzke Expanded Disability Status Scale (EDSS).

Method

37 patients with clinical diagnosis of MS and 22 healthy control subjects were investigated in a cross-sectional study using enzyme-linked immunosorbent assays (ELISA).

Results

Serum levels of sRAGE were found to be significantly lower in MS patients compared to levels in healthy controls (p = 0.005). A trend toward lower levels of serum sRAGE was observed in female MS patients compared to their male counterparts (p = 0.05). A relationship between sRAGE and EDSS, and sRAGE and rate of clinical relapse was observed (p = 0.012).

Conclusion

The significant reduction of sRAGE in MS patients relative to healthy controls supports the potential role for RAGE axis in MS clinical pathology. Lower levels of sRAGE may be associated with enhanced inflammatory responses. Based on these observations, further investigations into the role of sRAGE in MS clinical pathology is warranted.

Key Words: soluble receptor • inflammatory markers • cytokines • biomarker • advanced glycation

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. J. Caillier, F. Briggs, B. A. C. Cree, S. E. Baranzini, M. Fernandez-Vina, P. P. Ramsay, O. Khan, W. Royal III, S. L. Hauser, L. F. Barcellos, et al. Uncoupling the Roles of HLA-DRB1 and HLA-DRB5 Genes in Multiple Sclerosis J. Immunol., October 15, 2008; 181(8): 5473 - 5480. [Abstract] [Full Text] [PDF]